Jason D. Fontenot's most recent trade in Sangamo Therapeutics Inc was a trade of 1,029 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on Aug. 25, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.77 per share. | 25 Aug 2023 | 1,029 | 137,300 (0%) | 0% | 0.8 | 792 | Common Stock |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 25 May 2023 | 1,029 | 138,329 (0%) | 0% | 1.3 | 1,369 | Common Stock |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 199,500 | 199,500 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 42,750 | 145,917 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 24 Feb 2023 | 6,559 | 139,358 (0%) | 0% | 2.7 | 17,447 | Common Stock |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.83 per share. | 25 Apr 2022 | 826 | 103,167 (0%) | 0% | 4.8 | 3,990 | Common Stock |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 121,770 | 121,770 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 45,100 | 103,993 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.90 per share. | 25 Feb 2022 | 6,248 | 58,893 (0%) | 0% | 5.9 | 36,863 | Common Stock |
| Sangamo Therapeutics Inc | Jason D. Fontenot | SVP, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.71 per share. | 25 Apr 2021 | 811 | 62,496 (0%) | 0% | 11.7 | 9,497 | Common Stock |